Celsion’s GEN-1 Shows Promise in Newly-diagnosed Advanced Ovarian Cancer Patients

Celsion’s GEN-1 Shows Promise in Newly-diagnosed Advanced Ovarian Cancer Patients
All ovarian cancer patients treated in the Phase 1b OVATION trial benefited from the combination of Celsion‘s GEN-1 with standard of care. The trial enrolled advanced ovarian cancer patients who never had been treated. Among them, 100 percent had at least stable disease, and 86 percent saw a reduction or complete elimination of their tumors

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *